Alantra, a global mid-market investment banking firm, has appointed Anthony Harrington as a partner based in the company’s London office.

As a member of Alantra’s international healthcare sector team, Harrington will work with business owners and management teams in the pharma services sector, as well as financial sponsors, generating off-market opportunities, providing buy-side advice and maximising value in sale processes. 

An advisor to the pharma services sector, Harrington has more than 15 years’ M&A experience in the healthcare sector having worked on more than 40 M&A transactions and a variety of strategic advisory projects for clients in the UK, US, Europe and Asia. 

Harrington previously held positions in the healthcare teams at Results International, Bear Sterns and Rothschild. He has advised pharma services business including Cherry Healthcare on its sale to Avenir Global, Prescient Healthcare Group on the investment from Baird Capital, Lucid Group on the investment from LDC, STEM on its £84 million sale to UDG, and Hive on its £50 million sale to St Ives.

Andy Currie, managing partner of Alantra’s UK advisory business, said: “Deep sector experience and senior-led transaction advice are key elements of the Alantra offering. This marries well with the needs of our healthcare clients and it is great to be able to welcome Anthony to the team. We are absolutely committed to attracting the highest-quality talent and investing behind our people in our chosen markets as we grow the Alantra business both in the UK and globally.”